Photodynamic therapy with an endocytically located photosensitizer cause a rapid activation of the mitogen-activated protein kinases extracellular signal-regulated kinase, p38, and c-Jun NH2 terminal kinase with opposing effects on cell survival

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1740-1750

  Weyergang, Anette ^a   Kaalhus, Olav ^a   Berg, Kristian ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHOTOSENSITIZING AGENT; STRESS ACTIVATED PROTEIN KINASE; TETRAPHENYLPORPHINE; UNCLASSIFIED DRUG; DI(4 SULFONATOPHENYL)DIPHENYLPORPHINE; DI(4-SULFONATOPHENYL)DIPHENYLPORPHINE; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE; PORPHYRIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; ENDOCYTOSIS; ENZYME ACTIVATION; METABOLISM; PHOSPHORYLATION; PHOTOCHEMOTHERAPY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; ENDOCYTOSIS; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RATS;

EID: 49849104330     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0020     Document Type: Article

References (35)

1. Berg K, Selbo PK, Prasmickaite L, et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res 1999;59:1180-3.
2. Hogset A, Prasmickaite L, Selbo PK, et al. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev 2004;56:95-115.
3. Dietze A, Selbo PK, Prasmickaite L, et al. Photochemical internalization (PCI): a new modality for light activation of endocytosed therapeuticals. J Environ Pathol Toxicol Oncol 2006;25:521-36.
4. Oliveira S, Fretz MM, Hogset A, Storm G, Schiffelers RM. Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA. Biochim Biophys Acta 2007;1768:1211-7.
5. Selbo PK, Sivam G, Fodstad O, Sandvig K, Berg K. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy. Int J Cancer 2001;92:761-6.
6. Ndoye A, Dolivet G, Hogset A, et al. Eradication of p53-mutated head and necksquamous cell carcinoma xenografts using nonviral p53 gene therapy and photochemical internalization. Mol Ther 2006;13:1156-62.
7. Nishiyama N, Iriyama A, Jang WD, et al. Light-induced gene transfer from packaged DNA enveloped in a dendrimeric photosensitizer. Nat Mater 2005;4:934-41.
8. Berg K, Dietze A, Kaalhus O, Hogset A. Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin. Clin Cancer Res 2005;11:8476-85.
9. Weyergang A, Selbo PK, Berg K. Photochemically stimulated drug delivery increases the cytotoxicity and specificity of EGF-saporin. J Control Release 2006;111:165-73.
10. Yip WL, Weyergang A, Berg K, Tonnesen HH, Selbo PK. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol Pharmacol 2007;4:241-51.
11. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004;1704:59-86.
12. Moor AC. Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B 2000;57:1-13.
13. McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 2006;8:1775-89.
14. Weyergang A, Selbo PK, Berg K. Y1068 phosphorylation is the most sensitive target of disulfonated tetraphenylporphyrin-based photodynamic therapy on epidermal growth factor receptor. Biochem Pharmacol 2007;74:226-35.
15. Tong Z, Singh G, Rainbow AJ. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from Photofrin-mediated photodynamic therapy. Cancer Res 2002;62:5528-35.
16. Hulley PA, Conradie MM, Langeveldt CR, Hough FS. Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. Bone 2002;31:220-9.
17. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20:7108-16.
18. Wong TW, Tracy E, Oseroff AR, Baumann H. Photodynamic therapy mediates immediate loss of cellular responsiveness to cytokines and growth factors. Cancer Res 2003;63:3812-8.
19. Assefa Z, Vantieghem A, Declercq W, et al. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem 1999;274:8788-96.
20. Berg K, Maziere JC, Geze M, Santus R. Verapamil enhances the uptake and the photocytotoxic effect of PII, but not that of tetra(4-sulfonatophenyl) porphine. Biochim Biophys Acta 1998;1370:317-24.
21. Prasmickaite L, Hogset A, Berg K. Evaluation of different photosensitizers for use in photochemical gene transfection. Photochem Photobiol 2001;73:388-95.
22. Candide C, Maziere JC, Santus R, et al. Photosensitization of Wi26-4 transformed human fibroblasts by low density lipoprotein loaded with the anticancer porphyrin mixture Photofrin II: evidence for endoplasmic reticulum alteration. Cancer Lett 1989;44:157-61.
23. Rodal GH, Rodal SK, Moan J, Berg K. Liposome-bound Zn (II)-phthalocyanine. Mechanisms for cellular uptake and photosensitization. J Photochem Photobiol B 1998;45:150-9.
24. Berg K, Madslien K, Bommer JC, Oftebro R, Winkelman JW, Moan J. Light induced relocalization of sulfonated meso-tetraphenylporphines in NHIK 3025 cells and effects of dose fractionation. Photochem Photobiol 1991;53:203-10.
25. Schieke SM, von Montfort C, Buchczyk DP, et al. Singlet oxygen-induced attenuation of growth factor signaling: possible role of ceramides. Free Radic Res 2004;38:729-37.
26. Dougherty MK, Muller J, Ritt DA, et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005;17:215-24.
27. Zhuang S, Demirs JT, Kochevar IE. p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide. J Biol Chem 2000;275:25939-48.
28. Xue L, He J, Oleinick NL. Promotion of photodynamic therapy-induced apoptosis by stress kinases. Cell Death Differ 1999;6:855-64.
29. Tong Z, Singh G, Valerie K, Rainbow AJ. Activation of the stress-activated JNK and p38 MAP kinases in human cells by Photofrin-mediated photodynamic therapy. J Photochem Photobiol B 2003;71:77-85.
30. Hendrickx N, Dewaele M, Buytaert E, et al. Targeted inhibition of p38a MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy. Biochem Biophys Res Commun 2005;337:928-35.
31. Solban N, Pal SK, Alok SK, Sung CK, Hasan T. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 2006;66:5633-40.
32. Hsieh YJ, Wu CC, Chang CJ, Yu JS. Subcellular localization of Photofrin determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: when plasma membranes are the main targets. J Cell Physiol 2003;194:363-75.
33. Crescenzi E, Chiaviello A, Canti G, Reddi E, Veneziani BM, Palumbo G. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol Cancer Ther 2006;5:776-85.
34. Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y, Hasan T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 2006;66:10953-8.
35. Seshadri M, Spernyak JA, Mazurchuk R, et al. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin Cancer Res 2005;11:4241-50.